GILD · News · 20261031N
Revenue Performance and Mix
GILEAD SCIENCES, INC. · 2026-10-31 · Importance 27 · Surprise 32 · No source text
Gilead Sciences reported Q3 2026 sales of $8.3 billion, up 6.8% year over year and above market revenue expectations. Full-year revenue guidance was $31.15 billion at the midpoint, 1.3% above analysts’ estimates. Q3 non-GAAP earnings were $2.55 per share, 16.2% above analysts’ consensus estimates.
Key facts
- Gilead Sciences' Q3 2026 sales were $8.3 billion, up 6.8% year over year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +6.4% | Gilead Sciences' Q3 2026 sales were $8.3 billion, up 6.8% year over year. |